Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorÇavdar, Eyyüp
dc.contributor.authorİriağaç, Yakup
dc.contributor.authorAvcı, Okan
dc.contributor.authorSeber, Erdoğan Selçuk
dc.date.accessioned2023-05-06T17:23:34Z
dc.date.available2023-05-06T17:23:34Z
dc.date.issued2022
dc.identifier.issn1022-386X
dc.identifier.issn1681-7168
dc.identifier.urihttps://doi.org/10.29271/jcpsp.2022.11.1420
dc.identifier.urihttps://hdl.handle.net/20.500.11776/12162
dc.description.abstractObjective: To evaluate the strongest prognostic factors in advanced gastric cancer. Study Design: Observational study. Place and Duration of Study: Department of Medical Oncology, Tekirdag Namik Kemal University, Tekirdag, Turkey, between March 2012 and April 2022. Methodology: Adult patients with metastatic cancer who had completed at least two months of chemotherapy, without any other comorbidity were included. Using Kaplan-Meier methodology and Cox regression methods, potential prognostic factors were analysed for overall survival. Two different models were created for multivariate analysis by using statistically significant factors in univariate analysis. Results: The median overall survival in 216 patients was 7.8 months. The univariate analysis showed that body-mass index, performance status, liver metastasis, albumin, gamma-glutamyl transferase, carcinoembryonic antigen, carbohydrate antigen (CA 19-9), neutrophil-lymphocyte ratio (NLR), systemic immune-inflammation index, albumin-to-alkaline phosphatase ratio, sodium-globulin ratio (SGR) prognostic nutritional index (PNI), albumin-bilirubin ratio, and albumin-globulin ratio were associated with survival. In Model 1, which included only laboratory indices, multivariate analyses revealed that NLR (p= 0.001), SGR (p=0.025), and PNI (p=0.032) were prognostic for overall survival. In Model 2, established with all parameters, NLR (p=0.003), albumin (p=0.003), performance status (p<0.001), and CA 19-9 (p<0.001) were found to be independent prognostic factors. Conclusion: Pretreatment NLR, SGR, PNI, albumin, performance status, and CA 19-9 are strong prognostic factors in patients with advanced gastric cancer. These prognostic factors, which are easily accessible in clinical practice, may be utilised as useful tools for clinicians.en_US
dc.language.isoengen_US
dc.publisherColl Physicians & Surgeons Pakistanen_US
dc.identifier.doi10.29271/jcpsp.2022.11.1420
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGastric canceren_US
dc.subjectPrognosisen_US
dc.subjectOverall survivalen_US
dc.subjectChemotherapyen_US
dc.subjectMetastasisen_US
dc.subjectPrognostic biomarkersen_US
dc.subjectTo-Lymphocyte Ratioen_US
dc.subjectPredicts Survivalen_US
dc.subjectIndexen_US
dc.subjectIndicatoren_US
dc.titleComprehensive Analysis of Prognostic Factors in Advanced Gastric Cancer Patients Treated with Chemotherapyen_US
dc.typearticleen_US
dc.relation.ispartofJcpsp-Journal Of The College Of Physicians And Surgeons Pakistanen_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalıen_US
dc.authoridseber, selcuk erdogan/0000-0001-9081-2405
dc.authoridCavdar, Eyyup/0000-0001-5885-3047
dc.identifier.volume32en_US
dc.identifier.issue11en_US
dc.identifier.startpage1420en_US
dc.identifier.endpage1424en_US
dc.institutionauthorÇavdar, Eyyüp
dc.institutionauthorİriağaç, Yakup
dc.institutionauthorAvcı, Okan
dc.institutionauthorSeber, Erdoğan Selçuk
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorwosidseber, selcuk erdogan/H-3327-2017
dc.identifier.wosWOS:000921592400009en_US
dc.identifier.scopus2-s2.0-85141226149en_US
dc.identifier.pmid36377008en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster